Patents by Inventor Arne Mork

Arne Mork has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of enantiomeric pure escitalopram
    Publication number: 20040192766
    Abstract: The present invention relates to the use of anantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.
    Type: Application
    Filed: August 20, 2003
    Publication date: September 30, 2004
    Applicant: H. Lundbeck A/S
    Inventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
  • Use of enantiomeric pure escitalopram
    Publication number: 20040192765
    Abstract: The present invention relates to the use of anatiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in “treatment resistant” patients.
    Type: Application
    Filed: August 20, 2003
    Publication date: September 30, 2004
    Applicant: H. Lundbeck A/S
    Inventors: Connie Sanchez, Jesper Lyng Jensen, Arne Mork
  • Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
    Publication number: 20030032636
    Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.
    Type: Application
    Filed: June 6, 2002
    Publication date: February 13, 2003
    Applicant: H. Lundbeck A/S
    Inventors: Thomas Ivo Franciscus Hubert Cremers, Hakan Vilhelm Wikstrom, Johan Antonie Den Boer, Fokko Jan Bosker, Bernard Hendrik Cornelis Westerink, Klaus Peter Bogeso, Sandra Hogg, Arne Mork